Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Shares Outstanding (Weighted Average) (2016 - 2025)

Guided Therapeutics' Shares Outstanding (Weighted Average) history spans 16 years, with the latest figure at $78.4 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 36.76% to $78.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $78.4 million, a 36.76% increase, with the full-year FY2025 number at $78.4 million, up 36.76% from a year prior.
  • Shares Outstanding (Weighted Average) hit $78.4 million in Q4 2025 for Guided Therapeutics, up from $76.4 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for GTHP hit a ceiling of $78.4 million in Q4 2025 and a floor of $49297.0 in Q1 2023.
  • Historically, Shares Outstanding (Weighted Average) has averaged $38.2 million across 5 years, with a median of $32.1 million in 2022.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): soared 262656.83% in 2021 and later plummeted 99.76% in 2023.
  • Tracing GTHP's Shares Outstanding (Weighted Average) over 5 years: stood at $13.4 million in 2021, then skyrocketed by 166.03% to $35.6 million in 2022, then decreased by 19.68% to $28.6 million in 2023, then surged by 100.59% to $57.3 million in 2024, then skyrocketed by 36.76% to $78.4 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for GTHP at $78.4 million in Q4 2025, $76.4 million in Q3 2025, and $73.6 million in Q2 2025.